We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bispecific Antibody Boosts Sensitivity of Brain Cancer PET Scans

By LabMedica International staff writers
Posted on 03 Nov 2015
A bispecific antibody was developed that is taken up by glioblastoma cells in a manner that increases the specificity and intensity of signals detected by PET (positron emission tomography) scanning.

Investigators at the University of Wisconsin (Madison, USA) used a click chemistry approach to synthesize an antibody that recognized both epidermal growth factor receptor (EGFR) and CD105. More...
Click chemistry generates substances quickly and reliably by joining small units together. It is not a single specific reaction, but is descriptive of a method for generating products that follows examples in nature, which also generates substances by joining small modular units.

CD105 (also known as endoglin) has a crucial role in angiogenesis, therefore, making it an important protein for tumor growth, survival, and metastasis of cancer cells to other locations in the body. EGFR is the cell-surface receptor for members of the epidermal growth factor family of extracellular protein ligands. Mutations affecting EGFR expression or activity could result in cancer.

The investigators created a bispecific antibody from CD105 and EFGR specific Fab fragments that also contained a radioactive label detectable by PET. The compound was injected into mice that had received human glioblastoma transplants, and after 36 hours the animals were examined by PET scanning.

Results published in the September 28, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed a significantly enhanced tumor uptake and tumor-to-background ratio (compared with each monospecific Fab tracer. The combination of highly specific tumor uptake of the signal with extremely low background noise enabled visualization of small tumor nodules (less than five millimeters in diameter).

Senior author Dr. Weibo Cai, associate professor of radiology and medical physics at the University of Wisconsin, said, "As we learn more about cancer and what distinguishes it from healthy tissue we are able to bring to bear our expanding ability to detect and manipulate genes, proteins, and other molecules, both for detection and for therapy."

Related Links:

University of Wisconsin



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.